ARTICLE SUMMARY:
While clinical research at most healthcare systems paused for much of this spring, with a fallout that has yet to be calculated, cancer trials have been an exception. We look at Novocure's ongoing studies.
COVID-19’s more significant challenge for Novocure Inc. has been keeping its clinical trials on track. Because cancer cells in almost all solid tumors undergo the same or similar mitosis, the company has a robust R&D program and is exploring TTF’s potential in multiple solid-tumor cancers.
